里昂发表研报指，创科(00669.HK) 在产品创新及解决方案开发方面的优势，应会进一步扩大其与同业之间的利润差距。
里昂预期，创科的品牌矩阵及与非住宅分销管道的紧密联系，将推动美沃奇(Milwaukee)的销售增长回到双位数。该行亦估计，在贸易不确定性方面，创科已显著提高其供应链弹性，减少中国对美国市场的曝险。因此相对其竞争对手，创科已作更好准备。
里昂亦指，由于贸易波动及销售及行政支出(SG&A)略高，故将创科2025及2026财年净利润预测分别下调4.4%及3.4%，并将其目标价由138元下调至135港元，重申“跑赢大市”评级。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-21 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.